| abstract |
The present invention relates to general macrocyclic peptide analogs which selectively inhibit HCV NS3 protease, preferably wherein the 1-carbon atom in the R1 moiety is of the (R) -configuration and D is in the color position A; W is nitrogen or methine; R21 is hydrogen or alkoxy; R22 is hydrogen, phenyl or optionally substituted heteroaryl; R3 is -NH-C (O) -R32, -NH-C (O) -OR32 or -NH-C (O) -NHR32 wherein R32 is alkyl or cycloalkyl; R4 is hydrogen or alkyl; D is an alkylene group of 6-8 atoms, optionally substituted and / or heteroatoms such as oxygen, sulfur or (substituted) nitrogen and / or unsaturated bond; and Carboxy or N-substituted carbamoyl and their salts or esters thereof, and pharmaceutical compositions containing them and, optionally, formulations thereof, for the treatment of HCV infections, the compounds are process preparation methods and certain synthesis intermediates. HE |